Remedy Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 26-12-2024
- Paid Up Capital ₹ 0.10 M
as on 26-12-2024
- Company Age 35 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.50 Cr
as on 26-12-2024
- Revenue 0.16%
(FY 2022)
- Profit -7.37%
(FY 2022)
- Ebitda -1.24%
(FY 2022)
- Net Worth 1.45%
(FY 2022)
- Total Assets -0.14%
(FY 2022)
About Remedy Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.50 Cr.
Divya Tekriwal and Gaurav Tekriwal serve as directors at the Company.
- CIN/LLPIN
U02423MP1989PTC005230
- Company No.
005230
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 1989
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- LocationIndore, Madhya Pradesh
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Remedy Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Divya Tekriwal  | Additional Director | 03-Sep-2015 | Current |
| Gaurav Tekriwal | Additional Director | 25-Apr-2015 | Current |
Financial Performance of Remedy Drugs.
Remedy Drugs Pvt Ltd, for the financial year ended 2022, experienced modest growth in revenue, with a 0.16% increase. The company also saw a slight decrease in profitability, with a 7.37% decrease in profit. The company's net worth moved up by a moderate rise of 1.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Remedy Drugs?
In 2019, Remedy Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Apollo Plantations Pvt LtdActive 35 years 9 months
Divya Tekriwal and Gaurav Tekriwal are mutual person
- Sundew Plantations Pvt.Ltd.Active 33 years 9 months
Divya Tekriwal and Gaurav Tekriwal are mutual person
- Sutlej Plantations Pvt.Ltd.Active 33 years 9 months
Divya Tekriwal and Gaurav Tekriwal are mutual person
Charges (Loans)
₹75.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 7.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Oct 2018 | Others | ₹7.50 Cr | Open |
How Many Employees Work at Remedy Drugs?
Unlock and access historical data on people associated with Remedy Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Remedy Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Remedy Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
